Meaningful thresholds for change in quantitative computed tomography–derived fibrosis extent in idiopathic pulmonary fibrosis

AbstractRationale. Validated thresholds for clinically meaningful change in quantitative computed tomography (QCT) for fibrosis extent across algorithms re

academic.oup.com

Out of the Blue: An AJRCCM Podcast | “Social Apnea”: Obstructive Sleep Apnea Is Exacerbated on Weekends

Dr. John Fleetham chats with Danny Eckert about his article, "Obstructive Sleep Apnea is Exacerbated on Weekends."

tinyurl.com

Association of a polygenic risk score with diagnosis and outcomes in idiopathic pulmonary fibrosis

AbstractRationale. Idiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive pulmonary fibrosis and high mortality. Genetic markers, summ

academic.oup.com

Identification of a conserved sequence of disease progression in idiopathic pulmonary fibrosis

AbstractRationale. Idiopathic pulmonary fibrosis (IPF) begins years before symptoms appear, but the natural history is incompletely understood.Objectives.

academic.oup.com

MMP12 induces fibrogenic macrophage differentiation to drive granuloma-associated cardiac fibrosis

AbstractRationale. Cardiac sarcoidosis is a granulomatous inflammatory disease that frequently progresses to irreversible myocardial fibrosis and lethal co

academic.oup.com

ADAMTS14 is a novel modulator of fibroblast mechanoactivation in pulmonary fibrosis

AbstractRationale. Yes-associated protein (YAP)-mediated fibroblast mechanoactivation is an important driver of fibrosis in idiopathic pulmonary fibrosis (

academic.oup.com

Emerging Investigators Highlight

The American Journal of Respiratory and Critical Care Medicine thanks all the authors in this issue for submitting their stellar work to the Journal. As pa

academic.oup.com

Acute exacerbation in fibrotic interstitial lung disease: an international working group report

Abstract. Acute exacerbations (AEs) occur both in patients with idiopathic pulmonary fibrosis (IPF) and those with non-IPF fibrotic interstitial lung disea

academic.oup.com

From mechanisms to clinical practice: introduction to an AJRCCM special section on interstitial lung disease

This issue's special section on interstitial lung disease (ILD) spans the translational spectrum of ILD research, encompassing clinical practice guidelines

academic.oup.com

Cystic fibrosis in 2026: game over, or game on? Introduction to an AJRCCM special section on cystic fibrosis

In the past 2 decades, there have been no more dramatic developments in the world of cystic fibrosis (CF), or perhaps any respiratory disease, than the adv

academic.oup.com

Blood transcriptomic signatures predict poor outcomes in drug-susceptible pulmonary tuberculosis in Brazil

AbstractRationale. Non-sputum biomarkers to monitor tuberculosis treatment and predict poor outcomes are lacking.Objectives. To evaluate host-blood transcr

doi.org

Identification of pulmonary arterial hypertension patients with venous or capillary involvement

AbstractRationale. While therapeutic advances have improved survival for patients with Group 1 pulmonary arterial hypertension (PAH), patients with Group 1

doi.org

Extracorporeal membrane oxygenation without invasive mechanical ventilation for acute respiratory distress syndrome: an international cohort study

AbstractRationale. In acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO) without invasive mechanical ventilation (IMV)

doi.org

Determinants of tidal recruitment/derecruitment assessed by electrical impedance tomography in spontaneously breathing acute respiratory distress syndrome patients

AbstractRationale. Tidal recruitment/derecruitment (R/D) is a well-known mechanism of lung injury in acute respiratory distress syndrome (ARDS) patients, b

doi.org

Extracorporeal life support in adult critically ill patients: mechanisms of benefit in respiratory and cardiac failure

Abstract. Extracorporeal life support provides temporary cardiorespiratory support for patients with severe, potentially reversible cardiac and/or respirat

doi.org

Noninvasive respiratory support for adult patients with acute respiratory failure: an official American Thoracic Society Clinical Practice Guideline

AbstractBackground. Acute hypoxemic and hypercapnic respiratory failure are among the most common reasons for ICU admission and need for invasive mechanica

doi.org

The frequent exacerbator phenotype in bronchiectasis revisited: data from EMBARC registry

AbstractRationale. The frequent exacerbator phenotype was previously defined using a threshold of ≥3 exacerbations per year in bronchiectasis. However, the

doi.org

From mild-to-moderate to severe asthma: risk factors and patient profiles from the NORDSTAR cohort

AbstractBackground. The progression from mild-to-moderate to severe asthma remains unclear. This study aimed to assess the risk of progression following th

doi.org

Airway microbiome diversity, intramucosal bacteria, and spatial immunity in asthmatic adults and controls

AbstractRationale. Asthma is characterized by disruption of the thoracic airway mucosae and loss of microbial diversity. Spatial profiling of the mucosal t

doi.org

Airway mucus plugs in asthma and chronic obstructive pulmonary disease: pathobiology, imaging, and implications for clinical trials

Abstract. Mucus plugs have been previously recognized as an important pathological feature in asthma and chronic obstructive pulmonary disease (COPD), but

doi.org

How the exposome shapes our respiratory health

The exposome, reflecting the totality of an individual's exposures, is dynamic and exerts both short- and long-term effects on respiratory health and disea

doi.org

Diagnostic criteria for invasive pulmonary aspergillosis in chronic obstructive pulmonary disease patients

Abstract. More than 400 million people have chronic obstructive pulmonary disease (COPD), with exacerbations representing a major health burden. Although t

doi.org

Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials

AbstractRationale. The efficacy and safety of astegolimab, an anti-ST2 monoclonal antibody, was evaluated in participants with chronic obstructive pulmonar

doi.org

Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials

AbstractRationale. Disease stability in chronic obstructive pulmonary disease (COPD) is a low disease activity state proposed as a treatment target.Objecti

doi.org

Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials

AbstractRationale. Blood eosinophil count (BEC) is a biomarker indicating type 2 inflammation in patients with chronic obstructive pulmonary disease (COPD)

doi.org

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study

AbstractRationale. Clinical trials of severe asthma therapies often exclude or underrepresent key patient populations.Objectives. To evaluate the effective

doi.org